BeiGene, Ltd. (BGNE): Price and Financial Metrics


BeiGene, Ltd. (BGNE): $347.69

-3.82 (-1.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BGNE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 476

in industry

BGNE POWR Grades


  • Value is the dimension where BGNE ranks best; there it ranks ahead of 69.72% of US stocks.
  • The strongest trend for BGNE is in Momentum, which has been heading down over the past 52 weeks.
  • BGNE's current lowest rank is in the Momentum metric (where it is better than 4.19% of US stocks).

BGNE Stock Summary

  • BGNE's price/sales ratio is 31.07; that's higher than the P/S ratio of 92.93% of US stocks.
  • With a year-over-year growth in debt of 187.01%, BeiGene Ltd's debt growth rate surpasses 94.64% of about US stocks.
  • Revenue growth over the past 12 months for BeiGene Ltd comes in at 299.9%, a number that bests 97.35% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to BeiGene Ltd, a group of peers worth examining would be ALNY, SGEN, QRVO, STM, and WDC.
  • Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.

BGNE Valuation Summary

  • In comparison to the median Healthcare stock, BGNE's EV/EBIT ratio is 171.33% lower, now standing at -20.9.
  • BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.
  • BGNE's price/sales ratio has moved down 35.8 over the prior 68 months.

Below are key valuation metrics over time for BGNE.

Stock Date P/S P/B P/E EV/EBIT
BGNE 2021-08-31 30.3 8.0 -21.9 -20.9
BGNE 2021-08-30 29.7 7.8 -21.4 -20.5
BGNE 2021-08-27 27.7 7.3 -20.0 -19.1
BGNE 2021-08-26 27.8 7.3 -20.1 -19.1
BGNE 2021-08-25 28.5 7.5 -20.6 -19.6
BGNE 2021-08-24 28.1 7.4 -20.3 -19.3

BGNE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BGNE has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
  • BGNE's asset turnover comes in at 0.168 -- ranking 211th of 681 Pharmaceutical Products stocks.
  • AADI, CPIX, and NAVB are the stocks whose asset turnover ratios are most correlated with BGNE.

The table below shows BGNE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.168 0.883 -0.377
2021-03-31 0.165 0.897 -0.358
2020-12-31 0.065 0.771 -0.552
2020-09-30 0.070 0.746 -0.678
2020-06-30 0.078 0.704 -0.890
2020-03-31 0.166 0.826 -0.893

BGNE Stock Price Chart Interactive Chart >

Price chart for BGNE

BGNE Price/Volume Stats

Current price $347.69 52-week high $426.56
Prev. close $351.51 52-week low $219.20
Day low $340.00 Volume 125,200
Day high $353.99 Avg. volume 265,929
50-day MA $367.80 Dividend yield N/A
200-day MA $336.18 Market Cap 32.47B

BeiGene, Ltd. (BGNE) Company Bio


BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.


BGNE Latest News Stream


Event/Time News Detail
Loading, please wait...

BGNE Latest Social Stream


Loading social stream, please wait...

View Full BGNE Social Stream

Latest BGNE News From Around the Web

Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

BeiGene''s Brukinsa Approved In Europe For Rare Type Of Blood Cancer

The European Commission has approved BeiGene Ltd''s (NASDAQ: BGNE ) BRUKINSA (zanubrutinib) for Waldenström''s macroglobulinemia (WM). WM is a type of non-Hodgkin lymphoma. This rare blood cell cancer is characterized by an excess of abnormal white blood cells in the bone marrow. The approval covers adult WM patients who Full story available on Benzinga.com

Benzinga | November 24, 2021

3,062 Shares in BeiGene, Ltd. (NASDAQ:BGNE) Acquired by California State Teachers Retirement System

California State Teachers Retirement System acquired a new position in BeiGene, Ltd. (NASDAQ:BGNE) during the second quarter, HoldingsChannel.com reports. The fund acquired 3,062 shares of the companys stock, valued at approximately $1,051,000. Several other institutional investors and hedge funds have also bought and sold shares of the stock. Parallel Advisors LLC boosted its holdings in []

Transcript Daily | November 24, 2021

10 Best China Stocks to Buy Now

In this article, we will discuss the 10 best China stocks to buy now. You can skip our detailed analysis of China’s stock market, and go directly to read the 5 Best China Stocks to Buy Now. According to a report published by Wall Street Journal, China’s key benchmark, MSCI China Index, gained 27% in […]

Yahoo | November 24, 2021

BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenströms Macroglobulinemia

BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces approval of BRUKINSA (zanubrutinib) in the European Union for treatment of adults with Waldenströms macroglobulinemia.

Business Wire | November 23, 2021

BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström''s Macroglobulinemia

EU approval follows recent approvals for BRUKINSAincluding U.S., China, Brazil, and Canada The approval is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (N

FinanzNachrichten | November 23, 2021

Read More 'BGNE' Stories Here

BGNE Price Returns

1-mo -2.80%
3-mo 15.20%
6-mo -5.26%
1-year 21.62%
3-year 141.60%
5-year 1,000.63%
YTD 34.56%
2020 55.88%
2019 18.18%
2018 43.53%
2017 221.87%
2016 N/A

Continue Researching BGNE

Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:

BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.849 seconds.